Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)

NCT05904691 is registered in ClinicalTrials.gov with Ocugenix Corporation as lead sponsor.

NCT NCT05904691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)
Lead sponsor
Ocugenix Corporation
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 1, 2023
Completion date
November 30, 2026
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration (namd)